Hyderabad-based HRV Pharma is investing ₹150 crore to expand its manufacturing capabilities in peptides and high-potency oncology active pharmaceutical ingredients (APIs), according to livemint.com. The company is allocating ₹100 crore specifically to build a new manufacturing facility dedicated to these specialized oncology APIs, marking a strategic shift in its business model.
This investment reflects HRV Pharma's transition from relying on existing manufacturing capacities to underwriting specialized production for products it owns and commercializes. The company, which has been operational for seven years, aims to strengthen its position in the niche market of peptides and high-potency oncology APIs by developing in-house manufacturing infrastructure, enhancing control over production quality and supply chain.
The move comes amid growing demand for advanced pharmaceutical ingredients in oncology, a sector witnessing rapid innovation and increasing global market size. HRV Pharma's focus on peptides and high-potency APIs aligns with broader industry trends where specialized drug manufacturing is becoming critical. This investment positions the company to compete with established players in the Indian pharmaceutical manufacturing landscape and potentially expand its export footprint.
HRV Pharma's ₹150 crore investment plan was disclosed on September 7, 2026, as part of its strategy to enhance manufacturing capabilities and commercialize proprietary products in the oncology segment, according to livemint.com.